|Articles|May 17, 2016

+$1B in Zika Funds Approved by US Senate

Author(s)Sarah Anwar

The Senate has voted to grant $1.2 billion in funding to fight the impending local transmission of the Zika virus in the United States.

The Senate has voted to grant $1.2 billion in funding to fight the impending local transmission of the Zika virus in the United States.

On May 13, 2016, the Centers for Disease Control and Prevention (CDC) announced that more than $85 million in repurposed funds will be going toward efforts to combat local Zika virus transmission. This decision came after Puerto Rico saw its first Zika-related death and microcephaly case. Although only 20% of Zika patients present with symptoms, an infection during pregnancy can result in serious complications, such as microcephaly and even stillbirth. Zika infection has also been associated with several neurological disorders in adults and children, such as Guillain-Barré syndrome.

In Senate we just passed $1.2 billion for #Zika. Hopefully House will soon do the same. Important we get ahead of this. #ZikaVirus

— Marco Rubio (@marcorubio) May 17, 2016

Earlier this year, President Obama requested that Congress grant $1.9 billion to fight active transmission of Zika within the United States. However, Republicans pushed back. As a result, 3 “competing plans” were presented to lawmakers.The funds would go towards efforts to prevent Zika, such as vector control, as well as diagnostic testing and vaccination.

Now, senators are also pushing for emergency funding to be granted with the same urgency for opioid and heroin abuse in the United States.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.